FDA Warning Letter Draft Pilot Covers QSR, 510(k) And Labeling Violations
This article was originally published in The Gray Sheet
Written explanations by manufacturers to FDA citations for quality system inspections, premarket notification submissions (510(k)) and labeling violations could prevent the agency from issuing a warning letter under a draft pilot program outlined in the Aug. 27 Federal Register.
You may also be interested in...
FDA's Center for Biologics Evaluation and Research should adopt the Center for Device and Radiological Health's warning letter pilot program for non-blood related devices, Gen-Probe Senior Director of Regulatory Affairs Glen Freiberg told an Oct. 6 session of the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.